These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29715194)

  • 1. Trends in the use of puberty blockers among transgender children in the United States.
    Lopez CM; Solomon D; Boulware SD; Christison-Lagay ER
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):665-670. PubMed ID: 29715194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
    Silverman LA; Han X; Huang H; Near AM; Hu Y
    J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histrelin for central precocious puberty-a single surgeon experience.
    Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
    J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.
    Klein KO; Soliman AM; Bonafede M; Nelson JK; Grubb E
    J Med Econ; 2020 Apr; 23(4):407-414. PubMed ID: 31766907
    [No Abstract]   [Full Text] [Related]  

  • 5. Histrelin implantation in the pediatric population: A 10-year institutional experience.
    Swendiman RA; Vogiatzi MG; Alter CA; Nance ML
    J Pediatr Surg; 2019 Jul; 54(7):1457-1461. PubMed ID: 30262200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing pediatric histrelin implantation to improve success rates in clinic without sedation.
    Krishna V; Lee SL; DeUgarte DA
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1443-1448. PubMed ID: 34407329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Histrelin Implantation at a Pediatric Tertiary Care Center.
    Mak A; Hwang R; Nace G; Allukian M; Nance ML
    J Surg Res; 2023 Nov; 291():73-79. PubMed ID: 37352739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
    Ray LA; Eckert GJ; Eugster EA
    J Pediatr Endocrinol Metab; 2023 Mar; 36(3):309-312. PubMed ID: 36625262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
    Lewis KA; Goldyn AK; West KW; Eugster EA
    J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
    Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition memories: experiences of trans adult women with hormone therapy and their beliefs on the usage of hormone blockers to suppress puberty.
    Giovanardi G; Morales P; Mirabella M; Fortunato A; Chianura L; Speranza AM; Lingiardi V
    J Endocrinol Invest; 2019 Oct; 42(10):1231-1240. PubMed ID: 30953318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
    Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resumption of puberty in girls and boys following removal of the histrelin implant.
    Fisher MM; Lemay D; Eugster EA
    J Pediatr; 2014 Apr; 164(4):912-916.e1. PubMed ID: 24433825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
    Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
    J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
    Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
    J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the "Off-Label" Use of GnRH Agonists Among Pediatric Patients in the United States.
    Lopez CM; Solomon D; Boulware SD; Christison-Lagay E
    Clin Pediatr (Phila); 2018 Oct; 57(12):1432-1435. PubMed ID: 30003804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
    Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).
    Olson-Kennedy J; Streeter LH; Garofalo R; Chan YM; Rosenthal SM
    Transgend Health; 2021 Feb; 6(1):36-42. PubMed ID: 33644320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.